viernes, 20 de septiembre de 2019

Highlights from European Society of Cardiology (ESC) Congress 2019 - BMC Series blog

Highlights from European Society of Cardiology (ESC) Congress 2019 - BMC Series blog

Ciarán Fitzpatrick

Ciarán Fitzpatrick

Editor at BMC Series
Ciaràn is an Editor for the BMC Series since March 2019. He obtained his BSc in Neuroscience from University College Dublin, MSc & PhD in Pharmaceutical Sciences from University of Copenhagen, Denmark. He researchs the neurochemical correlates of behaviour relevant to psychiatric disorders cross-species. Having most enjoyed the publishing process during his PhD, Ciaràn relocated to London to join BMC. He is committed to promoting valid science on open-access platforms.


Highlights from European Society of Cardiology (ESC) Congress 2019

BMC Cardiovascular Disorders traveled to Paris to attend the European Society of Cardiology (ESC) 2019 Congress held together with the World Congress of Cardiology. The overarching theme communicated to nearly 33,000 health professional delegates from 146 different countries was “Global cardiovascular health”. We highlight some of our most impactful moments from Congress.

Re-purposing of diabetic drugs to treat cardiovascular disorders
Four new ESC guidelines were released at the ESC Congress. One, released in collaboration with the European Association for the Study of Diabetes (EASD), details the management and prevention of CVD in patients with diabetes or prediabetes. These recommendations come after recent positive findings from large outcome trials with new classes of diabetes drugs, which demonstrated improvements in cardiovascular health independent of metabolic outcomes. These glucose-lowering compounds include the sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. These guidelines also aim to reclassify cardiovascular risk in diabetic patients based on co-morbidities, with the plan to prevent cardiovascular disorder (CVD) initiation in those at high risk. These guidelines are timely given the global prevalence of diabetes is set to rise to more than 600 million people by the year 2045.

No hay comentarios:

Publicar un comentario